ClinicalTrials.gg
RecruitingNCT04685226Updated Sep 2, 2025

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

A Phase 1/2 interventional study of ICP-723 in Solid Tumors, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 24 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
310
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors

Read the detailed description

Solid Tumors

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically confirmed surgically unresectable locally advanced or solid tumors or primary central nervous system (CNS) tumors..
  2. Age:

    Adult Cohort: Age ≥ 18 years; Adolescent cohort: 12 ≤ years \< 18 years.

  3. At least one as per RECIST1.1 criteria, or for primary CNS tumors, at least one measurable lesion as per RANO or INRC criteria.
  4. Adult cohort: PS score of 0-1;
  5. Adolescent cohort: (age ≥ 16 years) or Lansky (age \< 16 years) PS score > 60.
  6. > 3 months.
  7. Female patients or male patients of , who agree to use medically acceptable effective methods of throughout the study up to 12 weeks after the last dose of the study treatment.
  8. Patients who have signed the Form voluntarily and agree to follow the therapeutic regimen and the visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Any other active within 5 years prior to the first dose of the study drug.
  2. Prior anti-cancer treatment within 28 days prior to the first dose.
  3. Major surgical procedures within 4 weeks or minor surgical procedures within 2 weeks prior to the first dose of the study drug.
  4. A history of allergic disease, severe drug allergy, known to any component of the ICP-723 tablet formulation.
  5. Other situations that, in the investigator's opinion, would make the subject unsuitable for participation in the study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    ICP-723

    ICP-723

    Drug: ICP-723

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    To evaluate the safety and tolerability of ICP-723 at different doses in the treatment of advanced solid tumors;

    Time frame: Up to 12 months

  2. MTD

    To determine maximum tolerated dose (MTD)

    Time frame: Up to 2 Months

Secondary outcomes

  1. Cmax

    To preliminarily obtain pharmacokinetic (PK) data of ICP-723 in the treatment of advanced solid tumors include the peak plasma concentration (Cmax)

    Time frame: Up to 1 month

  2. ORR

    Objective Response Rate

    Time frame: Up to 2 months

07

Study locations

24 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jan 2028, 87 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 28, 2020
StartActual
Sep 27, 2020
Primary completionEst.
Jan 25, 2028
CompletionEst.
Feb 25, 2028
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04685226
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Sep 27, 2020
Primary completion
Jan 25, 2028 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Sep 2, 2025

Study contacts

Rui Hua Xu, MD
Contact
xurh@sysucc.org.cn
13922296676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zurletrectinib

Start the discussion